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Since the identification of mouse dendritic cells (DC) in the early 70s, all attempts to con-
sistently classify the identified functional DC subpopulations according to their surface
molecule expression failed. In the absence of DC lineage markers, a great variety of non-
congruent surface molecules were used instead. Recent advances in the understanding of
the involvement of transcription factors in the differentiation of DC subpopulations, together
with the identification of a lineage marker for cross-presenting DC, have now allowed to
establish a consistent and unified DC classification in the mouse. We demonstrate in the
present article that all conventional DC in the mouse can be universally subdivided into
either XCR1+ (“cross-presenting”) DC or SIRPα+ DC, irrespective of their activation sta-
tus. This advancement will greatly facilitate future work on the biology of mouse DC. We
discuss this new classification in view of current DC classification systems in the mouse
and the human.
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OVERVIEW
Dendritic cells (DC) were discovered by Steinman et al. already
in the early 70s (1). Nevertheless, it was until recently difficult to
unequivocally distinguish them from other related cell types such
as monocytes or macrophages. As a result, a combination of sev-
eral markers had to be used to define DC in flow cytometry and
histology. For practical purposes, mouse conventional DC today
are identified in flow cytometry as cells, which express the inte-
grin CD11c and high levels of MHC II, but lack expression of
T-, B-, and plasmacytoid DC lineage markers, and also molecules
characteristic for monocytes and macrophages. In the absence of
(sub-) lineage markers, also DC subpopulations could not easily
be defined using surface molecules. This has led over time to the
use of a great variety of surface markers distinguishing supposedly
functionally distinct DC subpopulations and made it difficult to
directly compare results between laboratories. Further complexity
was brought about by the observation that DC with an apparently
similar function had different phenotypes in lymphoid tissues ver-
sus peripheral organs. As a consequence, the division of DC into
subpopulations remained somewhat arbitrary, making the experi-
mental results, including gene expression studies, less informative.
Being central to the understanding of DC biology, the ques-
tion how mouse conventional DC should be divided into subsets
remained a matter of intensive scientific debate to this very day.
Recently, we identified the first molecule restricted in its expres-
sion to mouse DC (2). Based on a variety of experimental systems,
we then could demonstrate that the chemokine receptor XCR1 is
a lineage marker for cross-presenting DC (3), a DC subpopulation
playing an important role in the induction of CD8+ T cell cyto-
toxicity (see below). The use of an antibody directed to XCR1
allowed for the first time the unequivocal identification and thus
a precise phenotyping of cross-presenting DC in various body
compartments of the mouse (3–6).
With the ability to define the cross-presenting DC population,
it became possible to ask the question whether the remaining DC
could also be defined by their surface characteristics. The use of
an extended panel of antibodies directed to DC surface molecules
indicated that all XCR1− DC were characterized by expression
of SIRPα/CD172a in the intestine (4). In view of these results,
together with the data presented here, we now propose a new clas-
sification based on the expression XCR1 and SIRPα, which can
be used to define DC subpopulations in all lymphoid and non-
lymphoid compartments of the mouse. We hope that this classifi-
cation will greatly facilitate the study of DC biology in the future.
This article describes the various steps, which have led to the
establishment of this new DC classification system, and discusses
the implications for the understanding of human DC subpop-
ulations. Gene expression profiles and functional aspects of DC
subsets [recently reviewed by Ref. (7–10)] are taken into account
only as far as they contribute to the classification of mouse DC.
Monocyte-derived inflammatory DC and plasmacytoid DC are
not considered here, since they represent different cell lineages.
HISTORICAL DC CLASSIFICATION SYSTEMS
Work of numerous groups has established that at least two major
conventional DC populations exist in the mouse. In the late
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90s, a subset of DC was identified in lymphoid tissues, which
expressed the CD8α homodimer on the cell surface (and lacked
CD8β and CD11b), and these DC were hence termed “CD8+ DC”
(11). A major step forward in the understanding of DC biology
was the demonstration that CD8+ DC excel in antigen “cross-
presentation”, a process in which antigen is shunted into the MHC
I pathway and presented to CD8+ T cells (12–14). Further studies
demonstrated that mouse CD8+ DC are specialized in the uptake
and proteolytic processing of stressed cells and the subsequent
presentation of the derived peptides to CD8+ T cells (15–17).
In general terms, antigen cross-presentation allows an efficient
induction of CD8 T cell cytotoxicity to antigens originating from
cell-invading pathogens or mutated (cancer) cells.
After identification of CD8α as a relevant subset marker on
around 20% of DC in the spleen, the remaining splenic DC were
classified as CD4+ DC (60%) and double-negative DC (DN DC,
20%) in C57BL/6 mice (18). When Edwards et al. (19) performed
microarray gene expression profiling of splenic DC populations in
the mouse, they confirmed the differing nature of CD8+ DC, but
noticed only relatively minor differences in the gene expression
profiles of CD4+ and DN DC, and thus concluded that these two
populations are phylogenetically related. Later work based on tar-
geting of antigen directly to splenic DC subsets has confirmed the
superior capacity of CD8+ (DEC-205+/CD205+) DC for antigen
cross-presentation and at the same time demonstrated a higher
efficiency of CD8− (33D1+/DCIR2+) DC in the presentation of
antigen to CD4+ T cells (20).
While the phenotypical and functional classification of splenic
DC made substantial progress, the understanding of DC subpop-
ulations in peripheral lymphoid tissues and organs lagged behind.
CD8α was detectable on resident DC in all lymphoid organs, but
absent on DC in certain peripheral tissues and on DC migrating
from the periphery to lymph nodes (LN) (21, 22). Since CD8α
was less useful in the periphery, a different classification system
was established by subdividing DC into CD103+ and CD103−
populations (22–25). Antigen cross-presentation was shown to be
restricted to CD103+ DC residing in the lung, the intestine, and
skin-draining LN (22, 24, 25), suggesting a functional relationship
to the CD8+ splenic DC. However, it soon was recognized that
the CD103+ DC population is not homogenous and therefore the
exact relationship between peripheral DC and lymphoid-resident
DC remained unresolved.
INVOLVEMENT OF TRANSCRIPTION FACTORS IN THE
DIFFERENTIATION OF DC
A major step forward was brought about by work on the involve-
ment of transcription factors (TF) in the differentiation of DC.
A series of studies demonstrated that development of CD8+
splenic DC and their peripheral counterparts critically depend
on the TF IRF-8 (also designated ICSBP), Id2, and Batf3 (26–
31). The most informative turned out to be the Batf3-KO mouse,
where only the splenic CD8+ DC, the lung and dermal CD103+
DC, and the intestinal CD103+ CD11b− DC were absent and
thus could be identified as developmentally related (only later it
became apparent that other small DC populations with a dif-
fering phenotype were also Batf3-dependent, see below). At the
same time, this animal model showed clear deficits in antigen
cross-presentation (29, 31). Together, this work strongly indicated
that the Batf3-dependent DC were the cross-presenting DC lineage
in the mouse.
IDENTIFICATION OF A LINEAGE MARKER FOR
CROSS-PRESENTING DC
When searching for the function of XCL1, a chemokine secreted
by activated CD8+ T cells and NK cells (32, 33), we found that
the corresponding receptor XCR1 is exclusively expressed by a
subset of DC. This observation represented the first instance of
a surface molecule being restricted to conventional DC in the
mouse. Analyzing a XCR1-lacZ-reporter mouse (a system which
provides limited signal intensity and suffers from high back-
ground in some extra-splenic tissues when using fluorescein-di-
β-d-galactopyranoside as substrate in flow cytometry), we found
XCR1 to be expressed by 70–90% of CD8+ DC and by up to 8% of
DN DC in the spleen. Histological analyses further indicated that
other lymphoid tissues and peripheral organs contained XCR1+
DC (2). Using the same XCR1-reporter mice and extending the
flow cytometry studies to DC in LN and several organs, Crozat
et al. (34) found XCR1 signals essentially limited to CD103+
CD11b− DC, allowing them to postulate that expression of XCR1
defines mouse lymphoid-tissue resident and migratory DC of the
“CD8α-type.”
Further understanding of XCR1-expressing DC became pos-
sible with the development of a mAb specific for murine XCR1,
which offered high-resolution flow cytometry and also allowed
sorting of XCR1+ DC for functional assays. These studies (3) con-
firmed earlier findings with the lacZ-reporter system in the spleen
(2) that expression of XCR1 and CD8 overlap, but are not congru-
ent. In the lung, the intestine, in skin-draining, and mesenteric LN,
CD103+ CD11b− DC were found to be essentially XCR1+. How-
ever, additional XCR1+ DC populations could also be identified
there and these were negative for CD103 or positive for CD11b
(3, 4). Thus, the expression pattern of XCR1 differed from the
“CD8+” and “CD103+ CD11b−” DC phenotypes associated with
antigen cross-presentation in the past.
In experiments directly aimed to define the correlation between
XCR1 expression and Batf3-dependence of DC, it became apparent
that all XCR1+ DC (irrespective of their CD8, CD103, or CD11b
expression status), were absent in Batf3-KO mice (3, 4). Congru-
ent with this observation, the 20% of splenic CD8+ DC, which
are negative for XCR1, were preserved in Batf3-KO animals (3);
these particular CD8+ XCR1− DC apparently represent a dis-
tinct DC population with a very different gene expression profile
(35). Together, the studies demonstrated for DC in all tissues an
excellent and unique correlation between XCR1 surface expression
and dependence on Batf3 [for data and discussion on the correla-
tion between XCR1 and surface molecules preferentially expressed
on Batf3-dependent DC such as CD8, CD205, Clec9A/DNGR-1,
Itga8, and CADM1 see in Ref. (5)].
These correlation studies were very striking, but did not deliver
direct information on the functional role of XCR1+ versus XCR1−
DC. Only when functional assays using soluble and cell-associated
antigen were performed with splenic (3) and intestinal DC (4, 6), it
became apparent that antigen cross-presentation is the domain of
XCR1+ DC, in particular with cell-associated antigen. Conversely,
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the CD8+ DC negative for XCR1 were found to be incapable of
antigen cross-presentation (3).
The perfect correlation between expression of XCR1, Batf3-
dependence, and the ability to cross-present (cell-associated) anti-
gen in various organ systems (3, 4, 6) allow to conclude that
XCR1 expression generally demarcates the Batf3-dependent cross-
presenting DC, as postulated (3). Thus, XCR1 can be regarded as
the lineage marker for cross-presenting DC in the mouse.
ALL DC CAN BE CLASSIFIED INTO XCR1+ VERSUS SIRPα+ DC
IRRESPECTIVE OF THEIR ACTIVATION STATE
Is there a surface molecule which would define the remaining, the
XCR1− DC population? To examine this question, we re-analyzed
all of our correlation studies, which were based on the use of a
panel of antibodies directed to DC surface molecules (among oth-
ers CD11b, CD171a/SIRPα, DCIR2), and the use of two reporter
mice (CD207, CX3CR1). In all of our analyses, the only molecule,
which showed a consistent and full anti-correlation with XCR1
was CD172a/SIRPα, indicating that this surface molecule could
be used to positively demarcate XCR1− DC (3, 4). Based on these
studies, we have proposed that XCR1 and SIRPα can be used to
classify intestinal DC and possibly all DC in the mouse (4, 36).
In order to test the general applicability of this new classifi-
cation system and to make the XCR1 expression studies directly
comparable, we have now isolated DC from a greater variety of
lymphoid and non-lymphoid organs and analyzed them in par-
allel. As can be seen in Figure 1, XCR1 and SIRPα were found to
be clearly anti-correlated in all organs tested. At the same time, all
DC present in these organs could be assigned to either population.
Thus, the anti-correlation between XCR1 and SIRPα can now be
demonstrated in a great variety of tissues.
All published data on the anti-correlation of XCR1 and SIRPα
have been obtained in steady-state animals only. It was there-
fore important to test DC also under inflammatory conditions,
FIGURE 1 | Expression of XCR1 and SIRPα on DC in various tissues at
steady state and in inflammation. Cells from different tissues of C57BL/6
mice (either untreated or 14 h after injection of 10µg LPS i.v.) were isolated
after enzymatic digestion (except for the spleen), and DC from lamina
propria (LP), Peyer’s patches, and mesenteric LN were additionally enriched
by density gradient centrifugation as described before (3, 4). Cells from
brachial, axillary, and inguinal LN were pooled for the study of peripheral LN
DC. For flow cytometric analysis of XCR1 and SIRPα expression on DC,
gates were set on live CD90− CD19− CD317− CD11c+ MHC II+ cells for
thymus, spleen, peripheral and mediastinal LN, and on live CD45+ CD3−
B220− F4/80− CD11c+ MHC II+ cells for lung, Peyer’s patches, LP, and
mesenteric LN. DC from steady-state LN were separated based on their
MHC II expression levels into resident (MHC IIint) and migratory (MHC IIhigh)
populations.
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when many DC surface molecules are up or down regulated.
To this end, animals were injected with 10µg LPS i.v. and DC
examined 14 h later. Under these conditions, SIRPα expression
remained rather stable, while XCR1 was slightly down regulated in
some organs, however without compromising the discrimination
of XCR1+ DC from SIRPα+ DC (Figure 1). Thus, the subdivi-
sion of conventional DC based on the expression of XCR1 and
SIRPα appears to be universally applicable. With the commer-
cial availability of an antibody directed to mouse (and rat) XCR1
(clone ZET) this classification can now be generally tested under
all possible conditions.
SIRPα, also abundantly expressed on macrophages, neutrophils
and some non-lymphoid tissues, has been implicated in the con-
trol of cell phagocytosis (37, 38). Cells expressing CD47, the ligand
for SIRPα, appear to be protected from engulfment by phago-
cytic cells (37). It is thus intriguing to note that both CD205 and
Clec9A/DNGR-1 on XCR1+ DC may regulate cell phagocytosis
(and antigen processing) in a positive way (39, 40), and SIRPα
on XCR1− DC in a negative fashion. This functional feature may
possibly contribute to the division of labor between the XCR1+
and SIRPα+ DC populations.
All available data (gene expression profile, toll-like receptor
expression pattern in particular), indicate that XCR1+ DC are
a homogenous DC lineage. Does this mean that all XCR1+ DC
function in the same way? This may not be the case. It is of interest
in this context that only CD8+ (i.e., XCR1+) splenic DC expressing
CD103 were capable to take up cells and to cross-present their anti-
gen to CD8+ T cells in a previous study (41). Only approximately
50–60% of splenic CD8+/XCR1+DC express CD103 under non-
inflammatory conditions (3, 41), and the situation appears similar
in resident mesenteric LN (4, 42). It is therefore quite possible
that XCR1+ DC are functionally heterogenous in terms of cross-
presentation, depending on their activation state, their anatomical
positioning, and the upregulation of other molecules in reaction
to environmental cues.
ARE SIRPα+ DC HOMOGENOUS IN THEIR ONTOGENY AND
FUNCTION?
This question is largely unresolved at present. Edwards et al. (19)
showed that CD4+ DC and DN DC, which now would be grouped
together as SIRPα+ DC, have a highly similar gene expression pro-
file, suggesting one uniform population. Nevertheless, the authors
found some genes to be quite specifically expressed in either
population. Other reports also point to a possible ontogenic or
functional subdivision of SIRPα+ DC. For example, only a small
fraction of SIRPα+ DC in the spleen express CD8 and differ in
their expression profile from the remaining DC populations (3,
35). Mice with a CD11c-cre driven deletion of the TF Notch2
showed a rather specific ablation of CD103+ CD11b+ DC in the
intestinal system (representing an ablation of approximately 50%
of SIRPα+ DC), and these DC were identified as an obligate source
of IL-23 in the defense to C. rodentium (43). In another study,
depletion of only CD301b+ DC in the CD103− (and thus most
likely SIRPα+) fraction of dermal DC resulted in a severe impair-
ment of skin Th2 immunity (44). More studies will be required
to make the results comparable and to answer the question on the
heterogeneity of SIRPα+ DC.
CAN THE SUBDIVISION OF DC INTO XCR1+ AND SIRPα+ DC
BE ALSO APPLIED IN THE HUMAN?
In the human, in vivo experiments on the function of DC subsets
are not possible, access to DC in various compartments is limited,
and the frequency of DC in the blood is very low. As a result,
data on human DC are rather scarce. At the gene expression level,
it was established that mouse CD8+ DC correspond to human
CD141+ (BDCA3+) DC, and mouse CD11b+ DC to human
CD1c+ (BDCA1+) DC (45), the two identified human DC pop-
ulations (46). Support for this correlation came from functional
studies, which demonstrated a superior capacity of CD141+ DC
for cross-presentation (47–49). Gene expression studies rely on
previous sorting of DC populations and thus depend on the use of
“correct” surface markers. Regarding these surface markers, how-
ever, human DC somewhat differ from mouse DC. XCR1 is exclu-
sively expressed on CD141+DC,but not on all of them. Analyses of
DC obtained from peripheral blood, thymus, and spleen demon-
strated that an average of 80% of CD141+ DC express XCR1 (own
unpublished data). At the same time, all of the CD141+DC express
Clec9A/DNGR-1, which in the human appears to be restricted to
conventional DC, as it is not found on plasmacytoid DC (40, 50,
51). Thus, in the human, expression of XCR1 and Clec9A/DNGR-
1 is not fully correlated (own unpublished data), as is the case with
conventional DC in the mouse. CADM1, another surface mole-
cule tightly associated with Batf3-dependent cross-presenting DC
in the mouse, gives a bright signal in the human and is perfectly
correlated with CD141 [(52), and own unpublished data]. Thus, it
is possible that cross-presenting DC in the human can be demar-
cated by the co-expression of CD141, Clec9A, and CADM1. This
assumption is further supported by the observation that SIRPα on
DC in various human organs is correlated with CD1c and fully
anti-correlated with CD141 (own unpublished data). Thus, on a
broad scale, it is quite clear that the human CD141+ DC con-
tain the cross-presenting DC population. Whether all of CD141+
DC can cross-present or whether this function is restricted to the
XCR1+ CD141+ DC remains to be determined. Further detailed
insight into this question will require gene expression and func-
tional studies comparing the majority of CD141+ DC expressing
XCR1 and the 20% fraction of CD141+ DC negative for XCR1.
CONCLUSION AND PERSPECTIVES
In summary, recent developments in the field allowed major
progress in the classification of mouse and human DC. Partic-
ularly in the mouse, where the subdivision of DC was notoriously
difficult, the use of a general DC classification scheme based on
the expression of XCR1 and SIRPα will make experimental results
more precise and also more comparable. Without any doubt, the
use of additional surface molecules will continue to be necessary
in order to better understand the functional states of DC of a
given lineage. Thus the old “markers” such as CD4, CD8, CD11b,
or CD103 will not become obsolete, but they will obtain a new
role in the functional analyses of XCR1+ versus SIRPα+ mouse
DC subpopulations.
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